10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
One year after raising $800 million in a follow-on public offering, BeiGene has announced it will list on the Hong Kong stock exchange with an initial public offering (IPO) expected to bring in an even greater sum for the Beijing-based firm. 27 July 2018
In the 1980s, technologies such as DNA editing started to mature, creating a range of sophisticated and transformative therapeutic techniques - and a race to secure funding, technologies and expertise. 27 July 2018
Chinese immuno-oncology and immuno-inflammation specialist I-Mab Biopharma has signed a deal with Korea's ABL Bio Corporation focusing on bispecific antibodies. 27 July 2018
Along with announcing analysts’ expectation-beating financials, leading biotech firm Amgen's outlined planned executive succession to address upcoming departures of two executive vice presidents. 27 July 2018
East Coast, USA-based biotech firm bluebird bio has been granted an accelerated assessment by the European regulator for its LentiGlobin gene therapy. 27 July 2018
UCB rose 1.2% on Thursday after it published financial results for the first half of 2018. The Belgian drugmaker, which specializes in immunology and neurology, reported 5% sales increases and a 2% rise in overall revenue over the first half of 2017. 26 July 2018
Roche group member Genentech has revealed positive top-line results from the Phase II LADDER study of its investigational Port Delivery System with ranibizumab (PDS) in people with wet age-related macular degeneration (AMD). 26 July 2018
Investors were initially encouraged when early indications pointed to a positive response among Alzheimer’s patients among patients receiving an anti-amyloid beta protofibril antibody from US biotech Biogen and Japanese pharma major Eisai. 26 July 2018
A new report from industry analyst GlobalData identifies an opportunity for biotech firms to pursue drug candidates targeting metabolic disorders. 26 July 2018
At a meeting yesterday, the Pulmonary Allergy Drugs Advisory Committee of the US Food and Drug Administration gave a negative, non-binding opinion on the approval of the biological drug mepolizumab as an add-on treatment to inhaled corticosteroid-based maintenance treatment for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD) guided by blood eosinophil counts. 26 July 2018
As was widely expected, US biotech Gilead Sciences late yesterday posted another quarter of falling sales and profits, but surprised with the announcement that both its chief executive and chairman were departing from the company. 26 July 2018
Takeda has announced that Alunbrig (brigatinib) has passed its primary endpoint for use in anaplastic lymphoma kinase-positive (ALK+) locally advanced or metastatic non-small cell lung cancer (NSCLC). 25 July 2018
UK pharma major GlaxoSmithKline (LSE: GSK) today announced an agreement to leverage genetic insights for the development of novel drugs with a Silicon Valley, USA-based gene profiling firm, which includes making a $300 million investment in the company. 25 July 2018
Today San Francisco, USA-based biotech start-up Alector announced the closing of a $133 million Series E financing and for the first time revealed its first three programs focused on Alzheimer’s disease and frontotemporal dementia (FTD). 25 July 2018
Chinese biotech BeiGene has started a trial that could signal the suitability of its immune checkpoint inhibitor tislelizumab – in combination with chemotherapy – for a massive patient group. 25 July 2018
Merck & Co, known as MSD outside of the United States and Canada, has announced that Keytruda (pembrolizumab) met one of its primary endpoint for overall survival in head and neck squamous cell carcinoma. 25 July 2018
More than two years since the National Institute for Care Excellence (NICE) ruled that Vertex Pharmaceuticals' cystic fibrosis therapy Orkambi (lumacaftor/ivacaftor) was too expensive to be issued through the National Health Service (NHS), the US firm has hit out at Parliament and NHS executives over delays. 25 July 2018
USA-based CNS-focused biotech Zogenix’ positive results for its drug ZX008 (fenfluramine hydrochloride) and the subsequent approval that is likely to follow, will push Zogenix to become a key player in the epilepsy market. 25 July 2018
South Korean firm Kolon Life Science has agreed a deal to sell cell and gene therapy Invossa (TissueGene-C) in parts of China, pending regulatory approval. 24 July 2018
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024